Meeting
2017 Gastrointestinal Cancers Symposium
Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
Authors
Ivan Barrera
Segal Cancer Centre - Jewish General Hospital, McGill University, Montreal, QC, Canada
Ivan Barrera , Sabin Dragos Filimon , Jassy Meng , Tomas Kavan , Young soo Rho , Gerald Batist , Petr Kavan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 498)
DOI
10.1200/JCO.2017.35.4_suppl.498
Abstract #
498
Poster Bd #
N16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2015 Gastrointestinal Cancers Symposium
The value of tissue protein expression as a predictor of efficacy for first or second-line therapy (tx) in metastatic ductal pancreas cancer (PDAC) in patients (pts) receiving either gemcitabine (G)-based tx or 5FU (F)-based tx.
First Author: Lauren Carcas
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
First Author: Ramesh K. Ramanathan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba